StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
JPMorgan Upgrades Novavax (NVAX) to Neutral, 'Sanofi Licensing Deal Brings In Flu Heavy Weight and Lifts Going Concern'
May 10, 2024 9:27 AM
JPMorgan analyst Eric Joseph upgraded Novavax (NASDAQ: NVAX) from Underweight to Neutral.The analyst comments "On the back of the announced ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Hot Upgrades
Upgrades
Next Articles
Form 8-K NOVAVAX INC For: May 10
May 10, 2024 8:08 AM
Form 10-Q NOVAVAX INC For: Mar 31
May 10, 2024 8:06 AM
Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
May 10, 2024 7:42 AM
Novavax (NVAX) and Sanofi (SNY) Enter Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
May 10, 2024 4:48 AM
Novavax (NVAX) stock soars 120% as Sanofi deal 'kicks off a new chapter'
May 10, 2024 4:15 AM
Novavax (NVAX) Misses Q1 EPS by 13c; offers outlook
May 10, 2024 4:06 AM
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
May 10, 2024 2:15 AM
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
May 10, 2024 2:00 AM
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
May 10, 2024 2:00 AM
Form DFAN14A NOVAVAX INC Filed by: SHAH CAPITAL MANAGEMENT
May 8, 2024 4:54 PM
